Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Growth in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 291,500 shares, a growth of 140.3% from the October 31st total of 121,300 shares. Based on an average daily trading volume, of 266,300 shares, the days-to-cover ratio is presently 1.1 days. Approximately 11.5% of the company’s stock are short sold.

Aligos Therapeutics Trading Up 11.0 %

Shares of Aligos Therapeutics stock opened at $25.51 on Friday. The firm has a market capitalization of $91.58 million, a P/E ratio of -1.92 and a beta of 2.11. The business’s fifty day simple moving average is $11.83 and its 200 day simple moving average is $12.67. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The business had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same quarter in the previous year, the firm earned ($10.25) earnings per share. Analysts predict that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Several large investors have recently modified their holdings of ALGS. Armistice Capital LLC grew its holdings in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after buying an additional 363,000 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares during the period. Finally, Opaleye Management Inc. grew its stake in Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after acquiring an additional 333,000 shares in the last quarter. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).